Jessica E. Forsyth

Jessica E. Forsyth

Auto-generated profile, based on publicly available information

Jessica E. Forsyth

Sheffield Centre for Health and Related Research (SCHARR), University of Sheffield, Sheffield, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2021 in PLOS Biology
Verified
Journal Article
Open access
PDF file
JFJessica E. Forsyth
Jessica E. Forsyth
AAAli H. Al-Anbaki
Ali H. Al-Anbaki
RFRoberto de la Fuente
Roberto de la Fuente
NMNikkinder Modare
Nikkinder Modare
DPDiego Perez-Cortes
Diego Perez-Cortes
BPBerenika Plusa
Berenika Plusa
Architectural changes at the cellular and organism level are integral and necessary to successful development and growth. During mammalian preimplantation development, cells reduce in size and the architecture of the embryo changes significantly. Such changes must be coordinated correctly to ensure continued development of the embryo and, ultimately, a successful pregnancy. However, the nature of such transformations is poorly defined during mammalian preimplantation development. In order to quantitatively describe changes in cell environment and organism architecture, we designed Internal Versus External Neighbourhood (IVEN). IVEN is a user-interactive, open-source pipeline that classifies cells into different populations based on their position and quantifies the number of neighbours of every cell within a dataset in a 3D environment. Through IVEN-driven analyses, we show how transformations in cell environment, defined here as changes in cell neighbourhood, are related to changes in embryo geometry and major developmental events during preimplantation mammalian development. Moreover, we demonstrate that modulation of the FGF pathway alters spatial relations of inner cells and neighbourhood distributions, leading to overall changes in embryo architecture. In conjunction with IVEN-driven analyses, we uncover differences in the dynamic of cell size changes over the preimplantation period and determine that cells within the mammalian embryo initiate growth phase only at the time of implantation.

21 October 2025 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
JFJessica E. Forsyth
Jessica E. Forsyth
LULesley Uttley
Lesley Uttley
RWRuth Wong
Ruth Wong
SRShijie Ren
Shijie Ren
Background: Extrapolation of immature survival data is integral to health technology assessment (HTA) but is often associated with large uncertainty. Incorporation of expert judgements can help to address this uncertainty, but often these judgements are perceived as being “best guesses” due to a lack of methodological transparency. This review assesses the current implementation and reporting of structured expert elicitation for long-term survival outcomes in the broader literature and recent submissions to the National Institute for Health and Care Excellence (NICE). Methods: Three literature databases were searched: MEDLINE via Ovid, Embase, and Web of Science. The search algorithm included terms to identify articles which obtained expert judgements for survival extrapolation. A pearl-growing approach was also employed using three seed papers to supplement the electronic searches. To identify recent NICE technology appraisals in oncology, the NICE guidance database was searched. Results: The search of the broader literature identified six studies which utilised structured expert elicitation for long-term survival outcomes. Four NICE technology appraisals were identified to have used structured expert elicitation between October 2023 and October 2024. The reporting and conduct of elicitation for survival quantities was variable in detail and rigour in both the broader literature and NICE submissions. Despite the requirement for significant resource investment within the process, elicited values are variably used within analyses and are predominantly used as qualitative external validation. At all points throughout the elicitation, including planning, conduct and reporting, there appears to be a considerable lack of technical detail, which in the context of NICE appraisals may hinder full consideration of the elicited values by reviewing committees. Conclusions: Currently, the methods and limited reporting structures being used to elicit long-term survival outcomes are not fit for purpose. This review highlights key areas for improvement and identifies examples of good practice when conducting structured expert elicitations for long-term survival outcomes.

13 March 2026 in BMJ Medicine
Verified
Journal Article
Open access
PDF file
JLJoanna Leaviss
Joanna Leaviss
JFJessica E Forsyth
Jessica E Forsyth
ABAndrew Booth
Andrew Booth
DCDavid Coyle
David Coyle
GDGeorge Daly
George Daly
CBChristopher Burton
Christopher Burton
Objective: To assess the clinical effectiveness of non-pharmacological interventions for fatigue in adults with long term medical conditions. Design: Systematic review and network meta-analysis. Data sources: Medline, Embase, CINAHL, APA PsycInfo, Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials, from database inception to 28 September-3 October 2023, and updated 23-24 September 2024. Eligibility criteria for selecting studies: Randomised controlled trials of non-pharmacological interventions for fatigue in long term medical conditions where fatigue was a criterion for inclusion, the primary target of the intervention, or the primary or co-primary outcome. Excluded were studies of fatigue in people with cancer, in relation to or after infection, or resulting from injuries or developmental disorders. Studies were limited to European-style healthcare systems. Results: 88 randomised controlled trials were included, comprising 6636 participants for the end of treatment analyses, 1849 participants for the short term (≤3 months after the end of treatment) analyses, and 2322 participants for the long term (>3 months) analyses, allocated to one of 27 interventions. The most common condition studied was multiple sclerosis (51 studies). A range of interventions were identified, and heterogeneity was found within intervention groups and between individual interventions. Interventions varied by duration, delivery methods, and intensity. Compared with usual care, interventions based on cognitive behavioural therapy (CBT) significantly reduced fatigue at the end of treatment (standardised mean difference −0.63, 95% credible interval (CrI) −0.87 to −0.40, 17 studies) and at the long term follow-up (−0.40, −0.63 to −0.21, nine studies). Promotion of physical activity significantly reduced fatigue at all three time points: end of treatment (standardised mean difference −0.32, 95% CrI −0.62 to −0.01, seven studies), short term (−0.51, −0.84 to −0.17, one study), and long term (−0.52, −0.86 to −0.18, two studies). Self-management focusing on energy conservation was not significantly beneficial at the end of treatment (standardised mean difference −0.20, 95% CrI −0.52 to 0.12, 10 studies) or at the short term follow-up (−0.13, −0.51 to 0.25, seven studies) but at longer term follow-up, comparable benefit with other interventions was suggested (−0.42, −0.90 to 0.09, three studies). The standard deviation of the variation between studies in the end of treatment, short term, and long term network meta-analyses indicated moderate heterogeneity of studies in each of the analyses. No significant inconsistency was detected within the networks. Conclusions: Interventions that support individuals to increase physical activity or that are based on CBT were effective in reducing fatigue in people with long term medical conditions. The strength of the evidence was moderate to low. Although relatively few studies in any condition other than multiple sclerosis exist, the magnitude of effect seemed to be similar across different conditions. Systematic review registration: PROSPERO CRD42023440141.

3 August 2025 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Open access
SDSarah Davis
Sarah Davis
MMMon Mon-Yee
Mon Mon-Yee
ASAnthea Sutton
Anthea Sutton
JLJoanna Leaviss
Joanna Leaviss
JFJessica E. Forsyth
Jessica E. Forsyth
CBChristopher Burton
Christopher Burton
We aimed to assess the cost-effectiveness of non-pharmacological interventions for fatigue in patients with chronic conditions in the UK. This systematic review of cost-effectiveness studies aligns with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 statement. Data sources: Electronic databases and citation searches. Inclusion criteria: Studies including adults with one or more long-term health condition, either physical or mental. Exclusion criteria: Studies associated with cancer, long-COVID, post-viral fatigue, medically unexplained conditions, developmental disorders and injuries. Assessment: A single reviewer completed a two-stage sifting process. Four studies met the inclusion criteria. They included patients with either multiple sclerosis or inflammatory rheumatic conditions, and assessed either cognitive behavioral therapy (CBT) or a personalized exercise programme (PEP). CBT was either dominated by usual care or had an incremental cost-effectiveness ratio (ICER) over £30,000. PEP dominated CBT, with the ICER for PEP versus usual care ranging from £13,159 to £35,424. The economic literature on this topic is much more limited than the clinical effectiveness literature, both in terms of interventions and populations covered. Future research should focus on a de novo economic evaluation to identify interventions with a high potential to be cost-effective across multiple conditions. PROSPERO (CRD42023440141).

1 October 2023 in Journal of The Royal Society Interface
Verified
Journal Article
Open access
JFJessica E. Forsyth
Jessica E. Forsyth
JCJames Casey
James Casey
SCSimon L. Cotter
Simon L. Cotter
WPWilliam J. Parnell
William J. Parnell
TSTom Shearer
Tom Shearer

11 May 2026 in Applied Health Economics and Health Policy
Verified
Journal Article
Open access
PDF file
JFJessica E. Forsyth
Jessica E. Forsyth
MAMonika Achra
Monika Achra
JEJavier Baena Espinar
Javier Baena Espinar
MHMaximilian Hochmair
Maximilian Hochmair
ALAstra M Liepa
Astra M Liepa
SRShijie Ren
Shijie Ren
Background Extrapolation of overall survival in health technology assessment (HTA) is a key area of uncertainty, as equally well-fitting models can generate divergent lifetime projections. This can lead to significant implications for decision-making. Subject experts are often consulted on the plausibility of survival projections, but input is rarely obtained in a robust manner. Objective This case study applies guidance from the National Institute for Health and Care Excellence Decision Support Unit Technical Support Document (TSD) on using structured expert elicitation for long-term survival estimation (TSD 26). This study focuses on its feasibility of implementation from the perspective of a company preparing a HTA submission. Methods The REVEL trial, evaluating ramucirumab plus docetaxel for stage IV non-small cell lung cancer, was selected as a case study. The elicitation was based on the Sheffield Elicitation Framework (SHELF) and undertaken in accordance with TSD 26. Results Five experts from four countries attended across three virtual workshops. Experts provided quantitative judgements on overall survival at 4 years for the intervention and comparator from the REVEL trial. Qualitative discussion of the change in hazard and scenario testing demonstrated the internal consistency of experts’ judgments and provided valuable context for expert judgements. Group discussion in separate workshops posed challenges when the facilitation team had to relay the views of absent experts. Conclusions This case study demonstrates that it is feasible to follow the recommendations provided in TSD 26 when conducting elicitation for long-term survival outcomes and highlights the critical role of discussing the hazard function in group discussions.